ReviewCureus2025
Advances in Lung Cancer Screening and Management: A UK-US Comparative Narrative Review Informed by American Thoracic Society (ATS) 2025 Highlights.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This narrative review summarises key developments presented at the American Thoracic Society (ATS) 2025 International Conference and examines their relevance to lung cancer care in the United Kingdom, with particular emphasis on transatlantic differences between US and UK practice. Drawing on selected high‑impact plenary sessions, thematic symposia, expert panel discussions, and late‑breaking abstracts covering screening, diagnosis, staging, treatment, and survivorship, the review highlights advances in lung cancer screening eligibility, emerging artificial intelligence (AI) and radiomic tools for diagnostic support, updates to Tumour-Node-Metastasis (TNM) staging, and evolving approaches to quality‑of‑life assessment. UK‑specific perspectives are incorporated, including experience from a single National Health Service (NHS) tertiary centre involving patients diagnosed with lung cancer on clinico‑radiological grounds without tissue confirmation. Differences in diagnostic strategies, healthcare system design, and resource availability between the United States and the United Kingdom are explored to identify opportunities for shared learning and adaptation within NHS lung cancer pathways. This review aims to inform UK clinicians, multidisciplinary teams, and policymakers about international developments and their potential translation into contemporary UK clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.